Nobivac Tricat Trio

Item Number: NOBTRICAT

Choose Your Options:

  • 10 doses (no solvent)

    Usually dispatched on Tuesday if ordered within 5 hours and 31 minutes

    £ 81.85

  • 50 dose (no solvent)

    Usually dispatched on Tuesday if ordered within 5 hours and 31 minutes

    £ 363.75

Total: £0.00


Presentation Live vaccine containing per dose of 1 ml > 105.2 TCID50 Feline viral rhinotracheitis virus; > 104.7 pfu Feline calicivirus; > 104.2 TCID50 Feline panleucopenia virus. Uses For the active immunisation of cats to reduce clinical signs of disease following infection with feline viral rhinotracheitis virus (feline herpesvirus) and/or feline calicivirus. To prevent clinical signs of disease and leucopenia following infection with feline panleucopenia virus, and to reduce excretion of FHV and virulent FPLV. Specific claims An onset of immunity of 7 days after primary vaccination has been demonstrated for the feline calicivirus, feline rhinotracheitis virus and feline panleucopenia virus components. Dosage and administration The contents of one vial of reconstituted vaccine should be injected subcutaneously. Reconstitute immediately prior to use by the addition of the contents of one vial Nobivac Solvent, Nobivac FeLV or Nobivac Rabies. Sterile equipment should be used for administration. Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation. Primary course vaccination For the primary course vaccination, 2 doses are required with an interval of 3 to 4 weeks between vaccinations. The first dose may be administered to kittens from 9 weeks of age. Revaccination scheme To maintain protection a single annual booster dose is recommended. Further information Experience has shown that the maternal antibody status of kittens within a litter varies greatly and reliance should not be placed on serological examination of the queen alone. A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress. Contra-indications, warnings, etc Only healthy animals should be vaccinated. The vaccine may not be effective in cats incubating the disease at the time of vaccination. A slight transient swelling (<5mm) may be observed at the site of injection for one day. Where Nobivac FeLV has been used to reconstitute Nobivac Tricat prior to inoculation, a small, painless nodule at the site of vaccination is frequently observed. It can persist for up to 13 days post inoculation. In the rare event of a hypersensitivity reaction following vaccination, administer an antihistamine, corticosteroid or adrenaline, without delay and by the most immediate route. After administration of an overdose a transient swelling (<5mm) at the injection site may occur for six days. A transient increase in temperature and some lethargy may occur for one day. No specific treatment or antidote is recommended. Care should be taken to ensure correct systemic administration of the vaccine. Inadvertent nasal or oral dosing (e.g. by making an aerosol with the syringe, or the cat licking the injection site) may result in clinical signs of respiratory disease including lethargy and malaise. Swabbing the injection site with spirit after vaccination is a useful precaution. Some animals may be immunologically incompetent and fail to respond to vaccination. Animals that have received the corresponding anti-serum or immunosuppressive drugs should not be vaccinated until an interval of at least 4 weeks has elapsed. Do not use in pregnant animals, as this has not been tested. No information is available on the safety and efficacy from simultaneous use of Nobivac Tricat with any other vaccine except Nobivac FeLV and Nobivac Rabies. It is therefore recommended that no other immunological product should be administered within 14 days before or after vaccination with Nobivac Tricat. Do not mix with any other medicinal product other than listed above. The efficacy of the FCV, FVR and FPLV components of the vaccine may be reduced due to maternal antibody interference. However, the vaccine has been proven to be of benefit against virulent challenge in the presence of maternal antibody levels to FCV, FVR and FPLV that are likely to be encountered under field conditions. Withdrawal period Not applicable. For animal treatment only. Keep out of reach and sight of children. Pharmaceutical precautions Store and transport between +2ºC and +8ºC. Care should be taken to avoid prolonged or repetitive exposure to high ambient temperatures following withdrawal from the refrigerator prior to use - in hot summer conditions vaccine potency can be severely reduced within a few hours. After reconstitution use within 30 minutes. Disposal advice Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities. Legal category POM-V Packaging Quantities Clear glass Type I (PhEur) single dose vials with halogenobutyl rubber stopper, closed with a colour-coded aluminium cap.

Data Sheets

NOBTRICAT 10D: Data Sheet

NOBTRICAT 50D: Data Sheet